Abstract
Not all sarcoidosis patients need treatment. In about 40% of cases, disease will subside spontaneously. For the rest who need to be treated, older drugs like corticosteroids, methotrexate and hydroxychloroquine, as well as the more recent anti-TNF agents, will be effective in suppressing granulomatous inflammation in every organ involved in about 30% of cases. In 20% of the patients, disease will relapse upon discontinuation or tapering of treatment, and in 10% will progress (these two categories constituting chronic disease). In these cases, reinstitution of the same or alternative medication or a combination regimen is warranted. Drugs side-effects and patients comorbidities should be taken in consideration during the selection of the appropriate regimen.
Keywords: Sarcoidosis, treatment, corticosteroids, methotrexate, hydroxychloroquine, infliximab
Current Drug Therapy
Title: A Guide to Treatment of Sarcoidosis
Volume: 5 Issue: 2
Author(s): Ilias C. Papanikolaou, Hidenobu Shigemitsu and Om P. Sharma
Affiliation:
Keywords: Sarcoidosis, treatment, corticosteroids, methotrexate, hydroxychloroquine, infliximab
Abstract: Not all sarcoidosis patients need treatment. In about 40% of cases, disease will subside spontaneously. For the rest who need to be treated, older drugs like corticosteroids, methotrexate and hydroxychloroquine, as well as the more recent anti-TNF agents, will be effective in suppressing granulomatous inflammation in every organ involved in about 30% of cases. In 20% of the patients, disease will relapse upon discontinuation or tapering of treatment, and in 10% will progress (these two categories constituting chronic disease). In these cases, reinstitution of the same or alternative medication or a combination regimen is warranted. Drugs side-effects and patients comorbidities should be taken in consideration during the selection of the appropriate regimen.
Export Options
About this article
Cite this article as:
C. Papanikolaou Ilias, Shigemitsu Hidenobu and P. Sharma Om, A Guide to Treatment of Sarcoidosis, Current Drug Therapy 2010; 5 (2) . https://dx.doi.org/10.2174/157488510791065102
DOI https://dx.doi.org/10.2174/157488510791065102 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Impacts of Prebiotics and Probiotics on Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Review of Structures Containing Fullerene-C60 for Delivery of Antibacterial Agents. Multitasking model for Computational Assessment of Safety Profiles
Current Bioinformatics Insights into Ecto-5’-Nucleotidase as a New Target for Cancer Therapy: A Medicinal Chemistry Study
Current Medicinal Chemistry SJSZ Glycoprotein (38 kDa) Inhibits Cell Cycle and Oxidative Stress in N-Methyl-N`- nitro-N-nitrosoguanidine-induced ICR Mice
Anti-Cancer Agents in Medicinal Chemistry Development of Peptide and Protein Based Radiopharmaceuticals
Current Pharmaceutical Design Comparison Between the Maximum Standard Uptake Value and the Ratio of Lymph Node to Primary Tumor Attenuation in Head and Neck Cancers: A Prospective Study
Current Medical Imaging Analysis of Taiwan Patents for the Medicinal Mushroom “Niu-Chang- Chih”
Recent Patents on Food, Nutrition & Agriculture Nanotechnological Advances in the Treatment of Epilepsy
CNS & Neurological Disorders - Drug Targets Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development
Current Diabetes Reviews Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
Current Cancer Drug Targets Safety and Complications Reporting Update on the Re-Implantation of Culture-Expanded Mesenchymal Stem Cells Using Autologous Platelet Lysate Technique
Current Stem Cell Research & Therapy A Review on Exploring Better Safety Prospects in Managing Cancer using Liposomal Combinations of Food Bioactive Compounds and Anticancer Drugs: Combisomes
Current Drug Delivery Stem Cell Function, Self-Renewal, Heterogeneity, and Regenerative Potential in Skeletal Muscle Stem Cells
Recent Patents on Regenerative Medicine Cancer Risk and Nullity of Glutathione-S-Transferase Mu and Theta 1 in Occupational Pesticide Workers
Current Pharmaceutical Biotechnology Rhenium-188 and Copper-67 Radiopharmaceuticals for the Treatment of Bladder Cancer
Mini-Reviews in Medicinal Chemistry Diabetes-induced Epigenetic Signature in Vascular Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Current and Potential Treatments for Cervical Cancer
Current Cancer Drug Targets Potential Role of <i>In Vitro-In Vivo</i> Correlations (IVIVC) for the Development of Plant-Derived Anticancer Drugs
Current Drug Targets Plant Extracts and Isolated Compounds Reduce Parameters of Oxidative Stress Induced by Heavy Metals: An up-to-Date Review on Animal Studies
Current Pharmaceutical Design